Matthew Gonzalez, MD
Advanced Heart Failure and Transplant Cardiology · Grand Rapids, MINPI 1639445844
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 46.5% of the total. 2025 is the largest year on record at $11,206, 9.8 times the $1,141 reported in 2019.
Across 155 payments — averaging $143.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Cvrx, Inc.$6K
- Bayer$3K
- Abiomed$1K
- AstraZeneca$329
- Novartis$203
- plus $882 from 13 others
Across 11 payments — averaging $7461.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$82K
What the payments were for
- Consulting fees$5,77526%
- Speaking & faculty fees$3,24015%
- Travel & lodging$5,54225%
- Food & beverage$7,62734%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 77 | $10,315 |
| Cvrx, Inc. | 12 | $5,970 |
| Bayer | 5 | $3,399 |
| Abiomed | 12 | $1,100 |
| AstraZeneca | 12 | $329 |
| Novartis | 12 | $203 |
| Johnson & Johnson(2 entities) | 3 | $187 |
| Novus Surgical Consultants | 1 | $150 |
| Medtronic | 1 | $141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $95 |
| Livanova USA, Inc. | 1 | $79 |
| Pfizer | 4 | $64 |
| Merck | 3 | $52 |
| Endotronix, Inc. | 1 | $26 |
| La Jolla Pharmaceutical Company | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Neurelis, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$5,704
- CARDIOMEMS$3,479
- Kerendia$3,352
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,713
- HeartMate 3 Left Ventricular Assist Device$1,512
- CardioMEMS HF System$970
- MitraClip$168
- LCP$145
- HeartWare HVAD$141
- Impella$125
- WAINUA$118
How this compares
$22,198 in reported general payments places this provider in the 80th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 93 | $2,208,152 |
| VyndaqelTafamidis Meglumine | 18 | $411,365 |
| EntrestoSacubitril/Valsartan | 301 | $328,006 |
| EliquisApixaban | 136 | $143,836 |
| FarxigaDapagliflozin Propanediol | 144 | $130,816 |
| JardianceEmpagliflozin | 71 | $79,596 |
| Torsemide | 264 | $6,744 |
| Metoprolol Succinate | 263 | $6,478 |
| Eplerenone | 34 | $3,959 |
| Spironolactone | 303 | $3,518 |
| Potassium Chloride | 97 | $2,658 |
| Carvedilol | 124 | $1,867 |
| Atorvastatin Calcium | 94 | $1,824 |
| Amiodarone Hcl | 74 | $1,429 |
| Digoxin | 40 | $1,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $64 | $2,763,353247 claims |
| NovartisEntresto | $203 | $328,006301 claims |
| AstraZenecaFarxiga | $329 | $130,816144 claims |
| Boehringer IngelheimJardiance | $19 | $79,59671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
Other advanced heart failure and transplant cardiology in Grand Rapids
- David FerminGrand Rapids$105K
- Michael DickinsonGrand Rapids$80K
- Sangjin LeeGrand Rapids$25K
- Renzo Loyaga-RendonGrand Rapids$5K
- Ryan GrayburnGrand Rapids$4K
- Milena JaniGrand Rapids$3K
- Jennifer CowgerDetroit$165K
- Thomas CascinoAnn Arbor$39K
- Keith AaronsonAnn Arbor$22K
- Waleed Al-DarziDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.